Clinical trial
Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and…
NCT00226239 · University of Pittsburgh, Other · Completed
Key facts
| NCT number | NCT00226239 |
|---|---|
| Title | Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer |
| Official title | A Phase II Trial of Docetaxel, Cetuximab (C225), and Cisplatin Followed by Radiation, Cetuximab, and Cisplatin in Locally Advanced Head and Neck Cancer |
| Lead sponsor | University of Pittsburgh, Other |
| Collaborators | Bristol-Myers Squibb Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer |
| Intervention type | Drug, Procedure |
| Interventions | Docetaxel, Cisplatin, Cetuximab, Radiation Therapy |
| Enrollment | 39 |
| Start date | Oct 1, 2005 |
| Primary completion | Jul 1, 2013 |
| Completion | Jul 1, 2013 |
| First posted | Sep 26, 2005 |
| Last update posted | Jul 11, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: